Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04142307 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Biofeedback in Idiopathic Infantile Nystagmus Syndrome

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: May 8, 2024 to Apr 29, 2025
    • Study completion date: Dec 30, 2024 to Dec 30, 2027
    v7
  2. Primary completion date: Nov 28, 2023 to May 8, 2024
    • Study completion date: Jan 30, 2024 to Dec 30, 2024
    v6
  3. Primary completion date: Oct 15, 2019 to Nov 28, 2023v5
  4. Re-verified, no change to tracked fieldsv4
  5. Study completion date: Jan 30, 2022 to Jan 30, 2024v3
  6. Study completion date: Jan 30, 2020 to Jan 30, 2022v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Active eye movement control training, an old and still most prevalent intervention in low vision rehabilitation (LVR) was never used in nystagmus clinically. Biofeedback training (BT) is the latest and newest technique for oculomotor control training in cases with low vision when using available modules in the new microperimetry instruments. Laboratory studies in the literature highlighted positive benefits from using BT in nystagmus cases. The purpose of this study is to assess systematically the impact of BT in a series of cases with Infantile Idiopathic Nystagmus (IIN) and formulate guidelines for further use of this intervention in nystagmus cases in general.
Trial Details
NCT Number NCT04142307
Lead Sponsor Monica Daibert Nido
Conditions
(from sponsor)		 Low Vision in Children
Related terms Nystagmus, Pathologic
Enrollment 34 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov